Journal of Orthopaedic Nursing
Volume 10, Issue 3 , Pages 159-165 , August 2006

Biologic treatments for rheumatoid arthritis

References 

  1. Arnett FC, Edworthy SM, Block DA, McShane DJ, Fries JF, Cooper SN, et al. The American Rheumatism Association 1987: revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 1988;31(3):315–324
  2. British Society for Rheumatology, 2000. Guidelines for Prescribing TNF Blockers in Adults with Rheumatoid Arthritis. Report of a working party of the British Society for Rheumatology. BSR, London.
  3. British Thoracic Standards of Care Committee. BTS recommendations for assessing risk and managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF alpha treatment. Thorax. 2005;60:800–805
  4. Cohen JD, Zaltin S, Kaiser MJ, Bozonnat MC, Jorgensen C, Daures J, et al. Secondary addition of methotrexate to partial responders to evanescent alone is effective in severe rheumatoid arthritis. Annals Rheumatic Disease. 2004;63:209–210
  5. Frankl EV. Man’s Search for Meaning. Boston: Beacon Press; 1962;
  6. Isenberg D, Morrow J. Friendly Fire: Explaining Auto-immune Disease. Oxford: Oxford University Press; 1995;
  7. Klareskog L, Van der Heijde D, De Jager JP, et al. Therapeutic effect of the combination of evanescent and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681
  8. Lipskey PE, Van der Heijde DM, St Clair EW, Furst DE, Breeveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New England Journal of Medicine. 2000;343(22):1594–1602
  9. National Institute for Clinical Excellence, 2002. Guidance of the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology Appraised Guidance No. 36. NICE, London.
  10. Oliver SM. The immune system and new therapies for inflammatory joint disease. Musculoskeletal Care. 2003;1(1):44–57
  11. Prevoo ML, Van E’Haf MA, Van Leeuwen MA, Van De Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1995;38(1):44–48
  12. Risley S, Thomas MA, Bray V. Rheumatoid arthritis, new standards of care: nursing implications of infliximab. Journal of Orthopaedic Nursing. 2004;8(1):41–49
  13. Ryan S, Hassell A, Dawes P, Kendall S. Perceptions of control in patients with rheumatoid arthritis clinical research. Nursing Times. 2003;99(13):36–38
  14. Somerville M. Developing a service for biologic therapies: a personal experience. Musculoskeletal Care. 2003;1(1):34–43
  15. Watson K, Hyrich K. The role of the British society for rheumatology biologics register (BSRBR) and the NICE guidelines for anti-TNF therapy. Short report. Musculoskeletal Care. 2003;1(1):58–64
  16. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine. 1999;340:253–259

PII: S1361-3111(06)00075-6

doi: 10.1016/j.joon.2006.06.013

Journal of Orthopaedic Nursing
Volume 10, Issue 3 , Pages 159-165 , August 2006

Article Tools